Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMKWCTR)

Drug Name
GS-9973 Drug Info
Synonyms
Entospletinib; 1229208-44-9; GS-9973; Entospletinib (GS-9973); gs9973; UNII-6I3O3W6O3B; 6-(1H-Indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine; GS 9973; 6I3O3W6O3B; CHEMBL3265032; C23H21N7O; 6-(1H-Indazol-6-yl)-N-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine; Entospletinib [INN]; Entospletinib [USAN:INN]; 4puz; 6-(1h-Indazol-6-Yl)-N-[4-(Morpholin-4-Yl)phenyl]imidazo[1,2-A]pyrazin-8-Amine; GS-9973; Entospletinib; SCHEMBL2483776; GTPL7889; MolPort-035-395-879; HMS3653D13; EX-A1120; BCP09582; AOB87385
Cross-matching ID
PubChem CID
59473233
ChEBI ID
CHEMBL3265032
CAS Number
CAS 1229208-44-9
TTD Drug ID
D0G9AW

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.38 0.00e+0 34/36 (94.44%) RFC2;RFC5;RFC4;...
Spliceosome 2.17 0.00e+0 101/150 (67.33%) PUF60;PRPF4;HSPA2;...
Cysteine and methionine metabolism 2.16 0.00e+0 43/50 (86%) MAT2A;GCLC;BHMT2;...
Nucleotide excision repair 2.03 0.00e+0 40/47 (85.11%) RFC2;GTF2H3;RAD23B;...
Mismatch repair 1.93 2.62e-3 22/23 (95.65%) RFC2;RFC5;RFC4;...
Fanconi anemia pathway 1.93 2.18e-3 36/54 (66.67%) RAD51;USP1;RMI1;...
Aminoacyl-tRNA biosynthesis 1.90 3.74e-3 15/66 (22.73%) GATC;QRSL1;NARS2;...
Homologous recombination 1.88 3.27e-3 35/41 (85.37%) RAD51;RBBP8;BRCA1;...
Base excision repair 1.78 1.16e-2 29/33 (87.88%) FEN1;POLE3;POLD2;...
One carbon pool by folate 1.72 2.16e-2 15/20 (75%) SHMT1;DHFR;MTHFD1;...
Primary immunodeficiency 1.70 2.56e-2 33/38 (86.84%) LCK;BLNK;ADA;...
Cell cycle 1.66 3.00e-2 110/124 (88.71%) CDC20;CHEK2;CHEK1;...
Mannose type O-glycan biosynthesis 1.65 2.87e-2 14/23 (60.87%) RXYLT1;B4GAT1;CHST10;...
Phosphonate and phosphinate metabolism 1.65 2.76e-2 5/6 (83.33%) CHPT1;PCYT2
Tyrosine metabolism 1.65 2.66e-2 30/36 (83.33%) ALDH3A1;GSTZ1;GOT2;...
Phenylalanine metabolism 1.65 2.50e-2 14/17 (82.35%) ALDH3A1;GOT2;HPD;...
Lysine degradation 1.62 3.04e-2 51/63 (80.95%) DLST;DHTKD1;SUV39H1;...
Tryptophan metabolism 1.61 3.20e-2 35/42 (83.33%) DLST;DHTKD1;HADH;...
Ribosome biogenesis in eukaryotes 1.56 4.82e-2 52/108 (48.15%) HEATR1;NOP56;NAT10;...
Mitophagy -1.72 1.74e-2 56/68 (82.35%) MFN2;TBK1;UBC;...
Regulation of actin cytoskeleton -1.72 1.76e-2 185/218 (84.86%) BDKRB1;CYFIP1;ITGB6;...
TGF-beta signaling pathway -1.73 1.60e-2 81/94 (86.17%) PPP2CA;SMURF1;CREBBP;...
Cell adhesion molecules -1.75 1.34e-2 118/148 (79.73%) CDH2;NEO1;SIGLEC1;...
Th1 and Th2 cell differentiation -1.77 1.00e-2 80/92 (86.96%) STAT5B;NOTCH3;STAT1;...
Intestinal immune network for IgA production -1.78 1.04e-2 38/48 (79.17%) HLA-DPB1;IL15RA;HLA-DOB;...
Autoimmune thyroid disease -1.78 1.09e-2 46/53 (86.79%) IL5;HLA-E;HLA-DQA1;...
Platelet activation -1.79 8.65e-3 106/124 (85.48%) MAPK3;MYL12B;ITGB3;...
Transcriptional misregulation in cancer -1.79 9.04e-3 158/192 (82.29%) IL3;GADD45G;FOXO1;...
Staphylococcus aureus infection -1.80 9.47e-3 72/95 (75.79%) PTAFR;HLA-DRA;KRT10;...
Pancreatic secretion -1.80 9.94e-3 87/102 (85.29%) PLA2G5;RAB27B;CFTR;...
Malaria -1.80 9.16e-3 44/50 (88%) IL10;CR1;THBS2;...
C-type lectin receptor signaling pathway -1.81 8.98e-3 93/104 (89.42%) CD209;IL1B;STAT1;...
Salmonella infection -1.84 6.58e-3 198/249 (79.52%) CYFIP1;KIF5B;PLEKHM1;...
Graft-versus-host disease -1.89 5.44e-3 32/42 (76.19%) HLA-DPB1;IFNG;HLA-DOB;...
Leukocyte transendothelial migration -1.89 4.97e-3 90/114 (78.95%) MYL12B;RAC1;ICAM1;...
Toxoplasmosis -1.93 1.78e-3 103/112 (91.96%) STAT1;LAMB2;TYK2;...
Viral myocarditis -1.97 1.91e-3 53/60 (88.33%) HLA-E;ABL1;HLA-DQA1;...
Proteoglycans in cancer -1.98 2.07e-3 172/205 (83.9%) MAPK3;ITGB3;RAC1;...
Inflammatory bowel disease -2.00 2.26e-3 58/65 (89.23%) IL1B;IL17A;STAT1;...
Toll-like receptor signaling pathway -2.02 2.49e-3 94/104 (90.38%) FOS;MAP2K3;CD80;...
ECM-receptor interaction -2.02 2.76e-3 80/88 (90.91%) ITGA5;COL9A2;COL2A1;...
Asthma -2.04 3.11e-3 25/31 (80.65%) HLA-DRA;IL10;HLA-DPB1;...
Tuberculosis -2.09 3.55e-3 159/180 (88.33%) CD209;IL1B;IFNB1;...
Type I diabetes mellitus -2.10 4.14e-3 38/43 (88.37%) HLA-DPB1;IFNG;LTA;...
Focal adhesion -2.12 4.97e-3 180/201 (89.55%) ITGB6;MAPK3;MYL12B;...
Phagosome -2.13 3.11e-3 118/152 (77.63%) HLA-F;STX18;ITGB3;...
Allograft rejection -2.13 4.14e-3 32/38 (84.21%) IL5;HLA-E;HLA-DQA1;...
Leishmaniasis -2.22 0.00e+0 67/77 (87.01%) ITGA4;HLA-DOA;FCGR3B;...
Protein digestion and absorption -2.31 0.00e+0 78/103 (75.73%) CELA2A;CELA3B;SLC3A1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 4H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 4H, 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 4H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H